Recurrence of eosinophilic pneumonia after switching from mepolizumab to tezepelumab for worsening asthma in eosinophilic granulomatosis with polyangiitis
A 50-year-old woman with eosinophilic granulomatosis with polyangiitis had maintained glucocorticoid-free remission for approximately four years with mepolizumab monotherapy. Because asthma control gradually deteriorated despite sustained control of systemic disease, mepolizumab was replaced with tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin. Asthma symptoms improved rapidly, and fractional exhaled nitric oxide levels decreased. However, peripheral blood eosinophil counts progressively increased, and computed tomography approximately six months after the switch demonstrated recurrent eosinophilic pneumonia, with pulmonary consolidations closely resembling those at the initial presentation. Prednisolone and mepolizumab were reintroduced, resulting in rapid resolution of eosinophilia and pulmonary infiltrates. Glucocorticoids were subsequently discontinued again without recurrence. This case suggests that improvement in airway symptoms after biologic switching does not necessarily indicate adequate suppression of systemic eosinophilic inflammation. Even after prolonged glucocorticoid-free remission, replacement of interleukin-5-targeted therapy with thymic stromal lymphopoietin inhibition may permit recurrence of eosinophilic disease. Peripheral blood eosinophil counts and systemic manifestations should therefore be carefully monitored after such switching in patients with eosinophilic granulomatosis with polyangiitis.
Authors
- Ayaka Inoue
- Takashi Yamane (ORCID: https://orcid.org/0000-0001-5053-5933)
Institutions
- Kakogawa Central City Hospital (JP)
Publication Details
- Journal
- Modern Rheumatology Case Reports
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1093/mrcr/rxag108
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00